KRAS and lung adenocarcinoma: The frequency of CD63–BCAR4 in lung adenocarcinoma without EGFR and KRAS mutations could be estimated as approximately 3% based on the present study (1/29) and Wang’s study (1/33); however, it might be much lower in Caucasians and/or in smokers.